How might this impact on clinical practice or future developments? ► As autoantibodies and IFN play an important role in a variety of cell populations, autophagy may also be relevant for biomarker, translational and therapeutic studies in several immune related diseases. ► New insights into the molecular mechanisms of podocyte autophagy in LN may shed promising therapeutic strategies.
ABsTrACT
Objective More recent studies suggested that defects in autophagy contribute to the pathogenesis of SLE, especially in adaptive immunity. occurrence and progression of lupus nephritis (Ln) is the end result of complex interactions between regulation of immune responses and pathological process by renal resident cells, but there is still a lot of missing information for an establishment on the role of autophagy in pathogenesis of Ln and as a therapy target. Methods Systemic and organ-specific aetiologies of autophagy were first evaluated by autophagy protein quantification in tissue homogenates in MrL lpr/ lpr lupus prone and female C57BL mice. Analysis of gene expression was also adopted in human blood and urine sediments. then, some key mediators of the disease, including complement inactivated serum, IgG from patients with Ln (IgG-Ln) and interferon (IFn)-α were chosen to induce podocyte autophagy. podocyte injuries including apoptosis, podocin derangement, albumin filtration and wound healing were monitored simultaneously with autophagy steady-state and flux. results Elevated LC3B in kidney homogenates and increased autophagosomes in podocyte from MrL lpr/ lpr were observed. In humans, mrnA levels of some key autophagy genes were increased in blood and urinary sediments, and podocyte autophagosomes were observed in renal biopsies from patients with Ln. Complement inactivated serum, IgG-Ln and IFn-α could induce podocyte autophagy in a time-dependent and dosage-dependent manner, and by reactive oxygen species production and mtorC1 inhibition, respectively. Autophagy inhibition aggravated podocyte damage whereas its inducer relieved the injury. Conclusion podocyte autophagy is activated in lupusprone mice and patients with lupus nephritis. Increased autophagy is cytoprotective against antibody and interferon-α induced podocyte injury.
Systemic lupus erythematosus (SLE) is a spectrum of autoimmune disease in which defects can occur at multiple points of the immune cascade, resulting in a striking heterogeneity of clinical presentations. [1] [2] [3] [4] The central pathology is the recognition of, and reaction to, self-antigens by the immune system, leading to type I interferon signalling and the production of pathogenic autoantibodies, which mediate much of the disease. [1] [2] [3] [4] More recent genetic and cellular studies suggested that defects in the evolutionarily conserved catabolic pathway of autophagy contributed to the pathogenesis of SLE, especially in the adaptive immune response. [5] [6] [7] [8] [9] [10] [11] [12] Hypothesis-free genome-wide association studies and further follow-up studies revealed that variants locating in autophagy-related genes associated with susceptibility to SLE. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Increased ATG5, MAP1LC3B and BECN1 expressions were observed in blood of patients with lupus. 13 18 23 And exposure to serum from patients with active SLE in SH-SY5Y cells was associated with increased formation of autophagic vacuoles. 24 It was observed that
Basic and translational research autophagy was upregulated in B cells during plasma cell differentiation in SLE, 25 and macrophages from patients with SLE also exhibited increased levels of autophagy. 26 In a tolllike receptor 7 transgenic mouse model of lupus, ATG5-dependent B-cell autophagy was necessary for the induction of lupus-like disease. 27 In addition, autophagy in T cells from both lupus-prone mice and patients with SLE was deregulated and not distributed homogeneously. [28] [29] [30] More recently, it was observed that, in transgenic mouse models, disruption of LC3-associated phagocytosis (LAP) resulted in defective clearance of exogenous dead cells, leading to increased serum levels of anti-dsDNA antibodies, anti-nuclear antigens and inflammatory cytokines-all of which were hallmarks of SLE. 10 31 However, to what extent autophagy contributes to the organ damage in human SLE remains obscure.
Lupus nephritis (LN) is one of the most serious manifestations of SLE and is an important predictor of poor outcome. Occurrence and progression of LN is the end result of complex interactions between regulation of immune responses and pathological process involved by renal resident cells. Similar to other diseases, autophagy is also implicated in the pathological process of renal diseases. Studies from renal cells in culture, human kidney tissues and experimental animal models implicate that autophagy regulates many critical aspects of normal and disease conditions in the kidney. [32] [33] [34] [35] By specific gene knockout mice, it is indicated that constitutive and induced autophagy is a major protective mechanism against podocyte ageing and glomerular injury. 36 Also, LAP-deficient animals displayed indications of kidney damage and exhibited increased functional markers of kidney injury, 10 such as increased serum creatinine, blood urea nitrogen and proteinuria. And variants of APOL1 and MTMR3, key drivers in autophagy, have been associated with LNs. [37] [38] [39] Rapamycin/sirolimus, as an inhibitor of TOR, would activate autophagy and was observed to prolong survival, maintain normal renal function, normalise proteinuria, restore protein levels of podocyte-specific markers including nephrin and podocin, reduce anti-dsDNA titres, ameliorate histological lesions, and reduce Akt and mammalian target of rapamycin (mTOR) activation in LN. 11 40-45 But there is still a lot of missing information necessary for a full establishment on the role of autophagy in pathogenesis of LN and as a therapy target. Thus, the aim for the current study is to reveal the role and function of autophagy in kidney pathology in LN, checking whether modulating autophagic activity in certain cell types may be therapeutically beneficial.
MeTHOds

Patients and healthy donors
All the 44 patients, recruited from Peking University First Hospital, fulfilled the American College of Rheumatology revised criteria for the classification of SLE and were diagnosed with LN by renal biopsy. A total of 37 volunteer controls were reported to be healthy by medical examination.
Quantification of autophagy-related gene expression
The quantifications of autophagy-related gene expressions were conducted using both peripheral blood mononuclear cells (PBMCs, 13 patients with LN and 12 healthy donors) and urinary sediments (16 patients with LN and 15 healthy donors) (online supplementary methods and table 1).
Purification of IgG from patient sera
IgG were purified from sera of five patients with LN and five healthy donors by protein G affinity chromatography (GE Healthcare).
Mice
Ten female MRL
lpr/lpr lupus-prone mice and 10 control female C57BL mice were acquired from Nanjing Medical University. Thymus, spleen, inguinal lymph nodes and kidneys were harvested at 6 months. 46 Lupus nephritis was proven by pathology (online supplementary figure 1 ). All the procedures were approved by the Institutional Animal Care and Use Committee of Peking University First Hospital.
eleCTrOn MICrOsCOPy
Kidney tissue for electron microscopy was fixed in 3% glutaraldehyde and 1% osmium tetroxide (OsO4), followed by dehydration in graded ethanol series and washed with acetone, and finally embedded in Epon 812. Ultrathin sections were stained with uranyl acetate and lead citrate and examined with a transmission electron microscope (JEM-1230; JEOL, Japan).
A total of 20 human renal biopsy specimens were examined by light microscopy, immunofluorescence (IF) microscopy and transmission electron microscopy (TEM). The average number of autophagosomes per podocyte was counted.
Cell culture and treatments
The immortalised human podocyte cell line was a gift from Moin A Saleem 47 and the mouse podocyte was purchased from Cell Resource Centre of Peking Union Medical College (3111C0001CCC000230). Both human and mouse podocytes were cultured and differentiated as described in online supplementary methods.
Podocytes were maintained and exposed to complement inactivated sera from patients with LN, 24 purified IgG from patients with LN, purified IgG from healthy donors, and commercial IgG (Sigma, I4506) and interferon (IFN)-α 2 (PBL Interferon Source, 11 105-1) for human podocyte or IFN-α (PBL Interferon Source, 12 100-1) for mouse podocyte. For autophagy inhibition, 5 mM 3-methyladenine (3-MA, M9281; Enzo) and 20 µM bafilomycin A1 (BafA1, BML-CM110; Enzo) were used. And for autophagy induction, 400 µM rapamycin (BML-A275; Enzo) was added.
lentiviral vector infection
The immortalised human podocyte cell line was seeded at 1×10 5 cells/well in six-well plates and infected with lentivirus vector ATG5 shRNA (Hanbio, Shanghai, China) for 12 hours after 30 min incubation with polybrene. Then, the media was changed regularly and experiments were performed after 10 days in differentiation condition. An empty lentiviral vector (Hanbio) was used as the negative control (online supplementary figure 2).
Western blotting
The primary antibodies against SQSTM1/p62 protein (5114; CST), LC3B (L7543; Sigma) and ACTB/β-actin (sc-47778; Santa Cruz), podocin (ab50339; Abcam), RPS6KB (2708P; CST), phospho-RPS6KB (Thr389, 9205S; CST), RPS6 (2317S; CST), phospho-RPS6 (Ser240/244, 2215S; CST), EIF4B (3592P), phospho-EIF4B (Ser422, 3591; CST) and the horseradish peroxidase-conjugated secondary antibodies (sc-2004 and sc-2005; Santa Cruz) were used.
Immunocytochemical staining
Indirect immunofluorescence staining was performed as described previously. 48 49 The primary antibodies included 1:100 anti-LC3B (L7543; Sigma) or 1:100 podocin (ab50339; Abcam). Images were captured by IF microscopy (Zeiss, Oberkochen, Germany).
mrFP-GFP-lC3
To analyse autophagy flux, cells were infected with dual-tagged LC3 (mRFP-GFP-LC3) adenovirus (Hanbio Biotechnology) according to the manufacturer's instructions. GFP and mRFP dots/cell and the ratio of mRFP/GFP were used for quantitation of autophagy flux, and 20 cells were counted in each group.
Flow cytometry assay
Podocyte apoptosis was determined by flow cytometry using an Annexin V-PE apoptosis detection kit (559763; BD Biosciences, USA) following the manufacturer's protocol. Then 10 000 cells were analysed by FACScan flow cytometer (BD Biosciences) to analyse cellular apoptosis. The levels of intracellular reactive oxygen species (ROS) were determined by 2′, 7′-dichlorofluorescin diacetate (Sigma) assay.
In vitro 'wound healing' assay
It is assumed that foot process retraction is a migration event caused by podocyte injury. 50 Podocytes were thus seeded in six-well tissue culture dishes 10 days in 37°C for differentiation. At the time point 0 hour, the cell monolayer was wounded. Afterward, the cell culture medium was replaced by test medium containing either standard medium or medium supplemented with IFN-α with 3-MA or rapamycin or shATG5, or IFN-α, 3-MA, rapamycin, shATG5 alone. The wounds closure were observed at 12 hours by phase contrast microscopy and documented by photography. Each condition was examined in triplicates.
Albumin influx assay
The filtration barrier function of podocyte monolayer was evaluated by a simple albumin influx assay as described previously.
sTATIsTICAl AnAlysIs
All the analysis was done using SPSS V.14.0. All the results are presented as mean±SD. Two group comparisons were assessed by two-tailed t-test. Values of p<0.05 were considered statistically significant.
(Please refer to online supplementary methods for detailed information).
resulTs elevated lC3 quantification in kidney homogenates of Mrl lpr/ lpr mice
We first examined the LC3B protein quantification in the thymus, spleen, inguinal lymph node and kidney tissue homogenate from 6-month-old lupus-prone MRL lpr/lpr mice and C57BL6/J mice. It was observed that LC3B-II was decreased in MRL lpr/lpr spleen homogenate but increased in fraction of lymph nodes (online supplementary figure 3 ). No significant difference was observed in the thymus. Five (50%) MRL lpr/lpr murine lupus mice were histologically proven with glomerulonephritis at 6 months, and the level of LC3B-II significantly increased in kidney tissue homogenate from MRL lpr/lpr mice with nephritis, compared with MRL lpr/lpr mice without nephritis or C57BL6/J mice ( figure 1A ). figure 1D ). Urinary sediment analysis indicated significantly increased mRNA levels of ULK1 (p=0.035), BECN1 (p=0.021) and MAP1LC3B (p=0.04) (figure 1E) in patients with LN compared with healthy controls. But ATG5, ATG12 and ATG16 showed non-significantly differed expression (data not shown).
Observed podocyte autophagosome in renal biopsy from human patients with ln
Autophagosomes in podocyte were further analysed by TEM in 20 patients with LN (each five patients were selected in every subgroup of types II, III, IV and V according to 2003 ISN/ RPS classification of LN). Podocyte autophagosomes could be observed in 17 out of 20 patients (85%) with LN (figure 1F). And only three patients showed no podocyte autophagosome and were all belonging to subclass II. However, the number of autophagosomes per podocyte (ranged from 0 to 9) correlated with no clinical data (data not shown).
sera from patients with ln could induce podocyte autophagy in vitro
We hypothesised that a serum factor present with LN may induce podocyte autophagy. To test for the presence of such a factor, we incubated human podocytes in the presence of complement inactivated sera from healthy donors or LN. It indicated that autophagy was stimulated by sera from patients with LN compared with sera from healthy donors (1:10 dilution) (figure 1G). As sera contained multiple mediators in disease pathogenesis, we then focused on IFN-α and IgG from patients with LN (IgG-LN).
IFn-α could induce podocyte autophagy in vitro
IFN-α, a central cytokine in the pathogenesis of SLE, can induce and accelerate SLE tissue damage in patients and mice. It remained unknown whether IFN-α can induce autophagy in human and murine podocytes. We observed that treatment with IFN-α induced autophagy in both human and murine podocytes, as indicated by an increase of LC3B-II and a decrease of p62 expression. And this kind of induction was time and dose Basic and translational research dependent ( figure 2A-D) . Our results also showed enhanced LC3-II and p62 expression levels in IFN (−) podocytes from 6 h to 48 h, indicating that autophagic vacuole accumulation was partially attributed to impaired autophagic degradation.
By indirect immunofluorescence, a large number of GFP-LC3B puncta formed in the cytoplasm and the average number of GFP-LC3B puncta per cell was significantly increased after exposure to IFN-α (figure 2E-H) compared with untreated cells. And by checking autophagic flux by GFP-RFP-LC3 system, there were more GFP+RFP+LC3 puncta (autophagosomes) as well as GFP-RFP+LC3 puncta (autophagolysosomes) in podocytes under IFN-α treatment than in untreated controls, indicative of accumulation of LC3. When co-treated with the lysosomal inhibitor (bafilomycin A) to block autophagic flux, more autophagosomes (GFP+RFP+LC3) were observed ( figure 2I-L) . By Western blotting, it was observed LC3B-II protein quantification was significantly increased with co-treatment of bafilomycin A and IFN-α, compared with single (IFN-α treatment alone or bafilomycin A alone) or no treatment. It suggested that the treatment increased the synthesis of autophagy-related membranes instead of autophagic flux block (figure 2M-P).
IgG isolated from patients with ln could induce podocyte autophagy in vitro
Because most of the pathogenic autoantibodies were of IgG isotype, to examine the likely link between autoantibodies and the induction of autophagy in podocytes, IgGs were isolated. IgG from the sera of human patients with LN (IgG-LN), enrolled healthy donors (IgG-Control) and commercial immunoglobulin from healthy donors were adopted to stimulate podocytes in vitro. Podocytes exposed to IgG-LN displayed significantly elevated LC3B-II levels compared with exposure to IgG-Control and commercial IgG. This increase occurred in both a time-dependent and dose-dependent manner, peaking at 6 hours post-treatment ( figure 3A-F) . Simultaneously, the levels of p62 decreased in a time-dependent and dose-dependent manner in IgG-LN-treated podocytes. It was thus indicative of potent induction of autophagy.
Indirect immunofluorescence experiments also demonstrated an increased number of LC3-positive dots in podocytes with increased autophagic activity in response to IgG-LN. In untreated or IgG-Control-treated cells, only a few LC3 puncta were detected, but increased number of LC3-positive puncta could be observed after exposure to IgG-LN addition ( figure 3G-H) . Assays using GFP-RFP-LC3 further confirmed this. Podocytes treated with IgG-LN displayed increased mature GFP-RFP+autophagolyso-somes. An additive effect in increased levels of GFP+RFP+LC3 puncta (autophagosomes) in the presence of both IgG-LN and lysosomal inhibition (with bafilomycin A1) indicated that IgG-LN enhanced autophagic flux (figure 3I-J). Increased levels of LC3-II in the presence of lysosomal inhibition were also confirmed by Western blotting, which increased the confidence that an induction of autophagic process was observed (figure 3K).
IgG-ln regulated generation of rOs and podocyte apoptosis
ROS production was observed to be considerably increased in podocytes treated with IgG-LN in a dose-dependent manner (figure 3L). To study the effect of IgG-LN on podocyte apoptosis in vitro, podocytes were further treated with IgG-LN. Flow cytometry revealed that apoptosis rates significantly increased to threefold when treated with IgG-LN (13.9%) compared with no treatment (4.65%) ( figure 3M-N) . 
Basic and translational research
IFn-α treatment linked mTOrC1 inhibition and podocyte damage
It was reported that type I interferon induced autophagy in certain human cancer cell lines involving mTORC1 signalling. The activity of mTORC1 can be monitored by phosphorylation changes in downstream target proteins like RPS6KB and EIF4EBP1.
To examine the effect of IFN-α on mTORC1, human and mouse podocytes were treated with 1000 U for 6, 24 and 48 hours. We observed decreased phosphorylation of RPS6KB (Thr389) and decreased phosphorylation changes of two RPS6KB-dependent proteins, RPS6 (Ser240/Ser242) and EIF4B (Ser422) ( figure 4A-B) , indicating that IFN-α attenuated mTORC1 signalling. Direct inhibition of mTORC1 activity can lead to induction of autophagy.
IFN-α treatment was not observed to affect cell apoptosis (online supplementary figure 5 ). Thus, maintenance of integrity of the structure and function of podocytes were further checked. By immunofluorescence staining, it was observed that podocin was in derangement ( figure 4C-D) . Expression of podocin, a podocyte-specific marker, was detected to be decreased in IFN-α using western blotting analysis ( figure 4E ). The scratch gap 
Basic and translational research
dimension with IFN-α treatment for 12 hours was larger than with no treatment (online supplementary figure 6 ), implying some compromise of the migration capability by IFN-α treatment. To assess the functional consequence, we examined the filtration barrier function of podocyte by using a paracellular permeability influx assay, which measured the albumin flux rate across the differentiated podocyte monolayer. Differentiated podocytes were incubated with IFN-α for 12 hours and then subjected to albumin influx assay ( figure 4F ). As shown in figure 4G -H, addition of IFN-α increased albumin influx across the podocyte monolayer from 4.84±1.00 µg/mL to 8.14±0.32 µg/mL in the human podocyte and from 3.52±0.45 µg/mL to 6.43±0.96 µg/mL in the mouse podocyte. These results indicated that the filtration barrier function of podocytes was severely impaired by IFN-α.
Autophagy inhibition aggravated podocyte damage whereas its inducer relieved the injury
It was important to demonstrate an effect resulting from inhibition or stimulation of autophagy. We thus applied chemical sequestration inhibitors of autophagy, including 3-MA and wortmannin, which inhibited class I phosphoinositide 3-kinases (PI3Ks) as well as class III PtdIns3Ks. As they were not entirely specific, some data were confirmed using RNA silencing of ATG5. On the contrary, the most commonly used inducer of autophagy was rapamycin, an allosteric inhibitor of mTORC1, and was adopted as autophagy activator.
In IgG-LN-induced podocyte apoptosis, addition of autophagy inhibitor further increased frequencies of podocyte apoptosis, from 13.9% with IgG-LN alone to 19.8% and 24.6% with addition of wortmannin and 3-MA, respectively, whereas it seemed that addition of rapamycin could moderately decrease apoptosis induced by IgG-LN, from 13.9% to 11.3% ( figure 3M ). It suggested that induction of autophagy partly protected podocyte from IgG-LN-induced apoptosis and the inhibition of autophagy may aggravate .
It was observed that both IFN-α treatment and shATG5 could decrease podocin quantification, whereas rapamycin could partially restore its expression in IFN-α-treated cells. Inhibition of autophagy by 3-MA made podocin derangement more pronounced. In contrast, upregulation of autophagy with rapamycin could ameliorate podocin derangement to some extent ( figure 4C-D) . Compared with untreated cells, all IFN-a, 3-MA and shATG5 12-hour treatments could weaken the scratch healing potential to some extent. Combination of IFN-α and shATG5 and 3-MA made worse impaired podocyte migration. However, rapamycin can restore podocyte migration to some extent (online supplementary figure  6 ). In paracellular permeability influx assay, it was observed that inhibition of autophagy by 3-MA or shATG5 alone can significantly increase podocyte layer permeability, even more significant than addition of IFN-α. However, when combinational treatment was applied, a higher loss of podocyte layer permeability was observed. Inhibition of autophagy by adding 3-MA (16.00±0.80 µg/mL in human podocyte, 13.30±0.99 µg/mL in mouse podocyte) and shAtg5 (14.50±0.68 µg/mL in human podocyte) in IFN-α worsened podocyte barrier function with increased albumin influx. Induction of autophagy by rapamycin (6.64±0.48 µg/mL in human podocyte, 4.34±0.60 µg/mL in mouse podocyte) ameliorated this kind of podocyte injury ( figure 4G-H) . dIsCussIOn Autophagy, an intracellular degrading system, is highly dependent on lysosomes and has existed universally in eukaryotic cells. 52 As a 'nonselective' degradation system for long-lived cytoplasmic proteins and dysfunctional organelles, it has been repeatedly confirmed to be actively involved in pathogenesis in SLE, especially in systemic immunity. 10 25-28 30 36 38 53 54 The pathogenesis of LN involves pathomechanisms outside and inside the kidney. But there is a lack of investigation on autophagy inside the kidney in LN. Although some observational studies indicated autophagy involved in some other immune-related nephritis in recent years, 35 36 inconsistent conclusions have been made. There have been studies that provide evidence to support a cytoprotective role of autophagy and others that support deleterious effects of autophagy. It is plausible that it is context dependent.
In the current study, we first checked whether autophagy is involved in pathogenesis of LN. The data indicated that autophagy is activated in LN, especially in podocyte. In lupus-prone MRL lpr/lpr mice, we observed that the levels of autophagy varied in different immune organs of MRL lpr/lpr comparing with C57BL mice. In kidney tissues, the levels of autophagy were significantly elevated in MRL lpr/lpr mice with renal injury comparing with MRL lpr/lpr mice without renal injury and C57BL control mice. In addition, in patients with LN, we observed that the expression of autophagy-related genes were increased in PBMC and urinary sediments. It reinforced the notion that both aberrant systemic immunity and intrarenal immunopathology contribute to lupus nephritis, in which autophagy may exert an important effect. However, as PBMC and urinary sediments were all mixtures of different cell types, they may be not optimal specimens, but they both shed light on autophagy upregulation, which was also consistent with all the previous reports in SLE. [28] [29] [30] Isolation of blood lineage-specific lymphocytes and urine podocytes surely will be more illuminating in future non-invasive biomarker studies in the field of autophagy.
To understand the precise role of autophagy activation in renal injury response and the pathogenesis of LN, we further checked relations between autophagy induction and podocyte injury.
We observed that many of the most important mediators of the disease-patients' sera, patients' IgG and IFN-α-could induce autophagy in both murine and human podocytes. In general, baseline autophagy in mammalian systems occurs under normal conditions, but can be stimulated by various pathologies including by ischaemic, toxic, immunological and oxidative insults. Other autophagy stimulators are pharmacological agents like the macrolide antibiotic rapamycin, the best-known trigger for autophagy, which acts by inhibiting mTOR. Although previous studies showed that deregulated autophagy plays an essential role for the induction of SLE, the precise nature of the stimulus leading to increased autophagic activity in lupus is not defined. We checked the effect of key known mediators of lupus, including sera from patients, IgG-LN and IFN-α. Although complement was inactivated, sera contain multiple layers of mediators in disease pathogenesis, so we further focused on IgG from patients with LN (IgG-LN) and IFN-α. The production of pathogenic autoantibodies and type I interferon signalling are key pathogenic mechanisms in the development of SLE and LN.
2-4 55 It was reported that autoimmune mice with systemic inflammation but impaired autoantibody production were protected from LN. 55 It has been estimated that antidsDNA deposition in LN accounts for no more than 10%-20% of overall eluted IgG overall, implying that IgG not recognising DNA represents the vast majority of antibodies in glomeruli.
And it was reported that anti-podocyte antibodies in lupus nephritis were multiple and secondary events after autoantibody deposition included complement deposition, and activation of podocyte intracellular mediators such as phosphorylated protein kinase C and free oxygen radicals. And ROS played a key role in mediating autophagy formation in podocytes and determined podocyte depletion. We thus speculated that increased generation of ROS was associated with the IgG-induced autophagy in podocytes. Exposure of NZB/W mice to IFN-α can accelerate pathogenic autoantibody production, proteinuria development and glomerular IgG deposition. 56 And type I IFNs synthesised by resident renal cells (mesangial and endothelial cells) induced renal dysfunction, glomerulonephritis, crescent formation and tubulointerstitial nephritis. 57 We observed that autophagy activation negatively associated with podocyte injury. Terminally differentiated podocytes are vulnerable to various kinds of injury, and the loss of podocytes is considered a key feature of progressive glomerular disease. Podocyte injury is responsible for proteinuria, and loss of podocytes by cell death or detachment is a critical step for the progression of glomerular diseases. In LN, podocytes are injured at the structural and molecular level. 58 In the study, autophagosomes were observed in the podocyte but not in other glomerular resident cells (such as mesangial cells or endothelial cells), suggesting the regulation and function of autophagy is likely cell type and context specific. In clinical situations, it is difficult to demonstrate autophagy clearly in tissues of formalin-fixed and paraffin-embedded biopsy samples retrospectively because tissues fixed in formalin have low or no LC3 detectable. More recently, LC3B or GFP-LC3 has been used to monitor autophagy through indirect IF or direct fluorescence microscopy. However, it was reported that IF assay pointing to LC3 could not differentiate cell types in kidney tissues. 35 36 Thus, confirmatory data on involved cell types may warrant future transgenic mice study. We observed that autophagy levels negatively associated with podocyte apoptosis, derangement of podocin, paracellular permeability influx and albumin influx, which were all indicators of podocyte injury. And we observed autophagosomes in all proliferative classes except from some patients with class II. As type class II was characterised by fewer immune deposits and less podocyte injury compared with classes III-V, which may be the underlying cause for the difference in which autophagy was cytoprotective against damage caused by IgG-LN. Some observational studies also suggested increased autophagosomes were detected in podocytes in FSGS, membranous nephropathy and IgA nephropathy. 35 36 It thus highlighted the fundamental role of autophagy for the long-time maintenance of glomerular podocytes in LN and other immune-related glomerulonephritis. But we observed no clinical correlation. The reasons may be several. First, the occurrence of LN is the interaction outcome between systemic/local immunity and renal intrinsic mechanism by resident cells. Every patient has his own key pathophysiological pathway. Such is also the fact that no single histological lesion or score could precisely predict clinical findings. Second, to correlate every single histological lesion with clinical parameters, it may need hundreds of patients. Lastly but not the least, the formation of autophagosomes is to protect podocyte against damage, which is a feedback or compensatory mechanism instead of direct damage. The production of autoantibodies to self-antigens followed by formation of immune complexes in glomeruli was the core step in leading to nephritis in SLE. Serum IgG from patients with SLE could induce the apoptosis of endothelial cell 59 and induce autophagy of T lymphocytes. 29 And anti-dsDNA antibodies could bind to podocytes in vitro and in vivo, resulting in segmental effacement of podocyte foot processes and proteinuria. 60 61 Our data provided evidence that serum IgG from patients with SLE could induce apoptosis and also autophagy in podocyte. With the increase of the concentration of serum IgG from patients with SLE, more ROS produced and levels of LC3B increased in podocytes, suggesting that ROS mediated podocyte autophagy induction by IgG from patients with SLE. In contrast, consistent to previous report, 62 we observed that IFN-α was not involved in podocyte loss, but impairment of cell structure and function. We observed that the induction of autophagy correlated with mTORC1 inhibition in human and mouse podocytes and that autophagy ameliorated IFN-α-induced podocyte injury. Taken together, our data indicated that activation of podocyte autophagy protected from cell injury at least under conditions of IFN and IgG-LN, which was in accordance with the data that LAP-deficient mice showed nephritis and loss of autophagy in podocytes resulted in a markedly increased susceptibility to glomerulosclerosis. Similarly, based on reported in vivo models of kidney injury, autophagy is often regarded as a renoprotective factor in the development and progression of renal diseases. But a defect in autophagy regulation itself is not (yet) proven to be able to cause human kidney diseases. In this study, we also observed an association of autophagy with LN and then identified some factors that could lead to its occurrence, in which autophagy played a protective role in feedback. This explains some mechanism of autophagy and its role in LN. Future investigations, for instance by using cell-type-specific targeted autophagic gene knockout mice in LN, are necessary to elucidate and clarify the precise functional role of autophagy in renal injuries. As autoantibodies and IFN play an important role in a variety of cell populations, autophagy may also be relevant for biomarker, translational and therapeutic studies in several other diseases.
Last but not the least, in interventional study, we observed autophagy activator could protect podocyte injury whereas its inhibitor aggravated it. Rapamycin, also known as sirolimus, is considered to be non-nephrotoxic in the normal kidney. In most pathophysiological cases, rapamycin showed renal protection, including decreasing proteinuria in lupus-prone mice. 63 However, it may also produce renal injury, including increasing proteinuria in long-term therapy. The possible reason is, inhibition of mTOR activates autophagy, but prolonged starvation reactivates mTOR with degradation of autolysosomal products, and mTOR reactivation is required to regenerate functional lysosomes and completion of autophagic process. 64 In Mtor pod-KO mice or prolonged rapamycin treatment, mTOR activity is blocked at both points. 65 Thus, inhibition of mTOR activates autophagy, but mTOR reactivation is also blocked, resulting in disruption of autophagic flux. Development of de novo or worsening proteinuria is well recognised in patients with longterm use of rapamycin. Given that disruption of the autophagic pathway may play a role in the pathogenesis of proteinuria, therapy with mTOR inhibitors can be a double-edged sword with both favourable and unfavourable consequences. In our current assay, rapamycin was added in quite a short time period, and it supported its effects on autophagy activation and renal protection. Future more specific and selective regulators of the autophagic machinery (without off-target effects) are urgently needed. Intermittent upregulation of autophagy may be more effective with fewer side effects than chronic use of such strategy. And studies using targeted autophagic gene knockout mice or transgenic mice are necessary to elucidate and clarify the precise therapeutic role of autophagy in lupus nephritis.
We systemically checked autophagy in both lupus-prone mice and human patients, confirming the involvement of autophagy Basic and translational research Figure 5 Schematic of the key observations of the current study.
in LN, as the exact effect that autophagy might exert in renal disease is multifaceted and complex, depending on different stimulations, types of disease or cells. We have thus further taken multiple mediators of the disease in checking their effect in two different podocyte cell lines and by combining different autophagy detection systems, different types of injuries and different drug interventions. Combining assays with multiple confirmation, we concluded that increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in LN. However, there were also some limitations of the current study. First, we checked different autophagy levels in lupusprone mice; similar to previous reports, 28 53 it was observed that different tissues showed different autophagy states. But different mice models, metabolic state and time of assay may all be confounding factors. Future gene knockout or transgenic mice study will be more informative in explaining cause effect and intervention value. Second, we observed only IgG from patients with LN could induce autophagy, but how differences in the type of autoantibodies or glycosylation affect autophagy is not clear. Third, an optimal condition and therapeutic window in which induction of autophagy would yield protective effects is still not clear. Fourth, whether autophagy levels could be monitored as disease biomarker is still an open question.
In the current study, we evaluated the levels of autophagy in kidney in MRL lpr/lpr mice and patients with LN and further explored the role of autophagy in podocyte injury of LN. Notably, we found that induction of autophagy (rapamycin) protected podocyte from IgG-LN-induced apoptosis and IFN-α induced derangement of podocin and increased albumin influx. Likewise, drugs acting as autophagy inducers such as rapamycin were shown to be beneficial in LN treatment. Our findings proved the protective role of autophagy in LN, especially in the podocyte (figure 5). New insights into the molecular mechanisms of podocyte autophagy in LN may shed promising therapeutic strategies.
